Floatz logo

Florbetaben

Amyotrophic Lateral Sclerosis

National Institute of Mental Health (NIMH)Small moleculePhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

147 Active assets in the Amyotrophic Lateral Sclerosis cohort.

Asset / SponsorPhaseRating
Taurursodiol
Amylyx Pharmaceuticals Inc.
Phase 3BBB
Tofersen
Biogen
Phase 4BBB
Riluzole
AB Science
Phase 4BB
Mexiletine
Bjorn Oskarsson, MD
Phase 4BB
Diacetyl(N(4)-Methylthiosemicarbazonato) Copper (Ii)
Collaborative Medicinal Development Pty Limited
Phase 2/3BB

View all 50 →

Same molecule, other indications

Florbetaben is also rated in:

Alzheimer diseaseActive
BBB
Indicative · Phase 4
73 / 100
View asset →
AL amyloidosisActive
B
Indicative · Phase 3
60 / 100
View asset →
dementiaActive
CC
Indicative · Phase 1
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →